University of Michigan - Ann Arbor

219 individuals tested positive for the antibodies, with seroprevalence increasing from 5% to 11% over the course of the 5-week study. The authors estimated an overall seroprevalence in the general population of Geneva using a Bayesian logistic regression model to be 4.8% (95% CI 2.4-8.0) the first week, 8.5% (95% CI 5.9-11.4) the second, 10.9% (95% CI 7.9-14.4) the third, 6.6% (95% CI 4.3-9.4) the fourth, and 10.8% (95% CI 8.2-13.9) the fifth.

Seroprevalence among the subset from the Bus Sante study revealed similar RR estimates for 65+ and across genders in this study. When the authors ran the confirmatory test, they found their estimates were very relatively unchanged.

Results: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Stringhini, S., Wisniak, A., Piumatti, G., Azman, A., Lauer, S., and H. Baysson. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. (2020). 
*https://doi.org/10.1016/S0140-6736(20)31304-0

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Risk of seropositivity across demographics
- Comparable across gender (RR 1.26 [95% CI 1.00–1.58])
- Age: 5-9 years and 65+ were lower than 20-49 years, RR 0.32 (0.11–0.63) and RR 0.5 (0.28-0.78), respectively
- 17.1% of children 5-9 had one or more seropositive family member
- 3% of adults 65+ had a seropositive family member

Risk of seropositivity across demographics: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

"Seroprevalence estimates and 95% CIs for each week of the survey (A), daily confirmed COVID-19 cases reported in Geneva (B), and cumulative case counts per day and cumulative incidence rate of confirmed COVID-19 (C)".
Red shading shows the sampling periods for each week.

Learn Before

Related